APOLLO ENDOSURGERY INC (APEN)

US03767D1081 - Common Stock

10  +0.08 (+0.81%)

After market: 9.99 -0.01 (-0.1%)

Fundamental Rating

1

APEN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of APEN have multiple concerns. APEN is valied quite expensively at the moment, while it does show a decent growth rate.



0

1. Profitability

1.1 Basic Checks

APEN had negative earnings in the past year.
In the past year APEN has reported a negative cash flow from operations.
APEN had negative earnings in each of the past 5 years.
In the past 5 years APEN always reported negative operating cash flow.

1.2 Ratios

APEN has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 55.20%, APEN perfoms like the industry average, outperforming 52.58% of the companies in the same industry.
In the last couple of years the Gross Margin of APEN has declined.
APEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.92%
GM growth 5Y-2.23%

1

2. Health

2.1 Basic Checks

APEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for APEN has been increased compared to 1 year ago.
APEN has more shares outstanding than it did 5 years ago.
APEN has a worse debt/assets ratio than last year.

2.2 Solvency

APEN has an Altman-Z score of -0.16. This is a bad value and indicates that APEN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.16, APEN is doing worse than 60.56% of the companies in the same industry.
A Debt/Equity ratio of 1.04 is on the high side and indicates that APEN has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.04, APEN is doing worse than 79.34% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.04
Debt/FCF N/A
Altman-Z -0.16
ROIC/WACCN/A
WACC10.2%

2.3 Liquidity

APEN has a Current Ratio of 2.35. This indicates that APEN is financially healthy and has no problem in meeting its short term obligations.
APEN's Current ratio of 2.35 is on the low side compared to the rest of the industry. APEN is outperformed by 66.20% of its industry peers.
APEN has a Quick Ratio of 1.89. This is a normal value and indicates that APEN is financially healthy and should not expect problems in meeting its short term obligations.
APEN's Quick ratio of 1.89 is on the low side compared to the rest of the industry. APEN is outperformed by 60.56% of its industry peers.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 1.89

5

3. Growth

3.1 Past

APEN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.99%.
APEN shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.01%.
The Revenue has been growing slightly by 3.63% on average over the past years.
EPS 1Y (TTM)-9.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.21%
Revenue 1Y (TTM)22.01%
Revenue growth 3Y14.87%
Revenue growth 5Y3.63%
Sales Q2Q%31.8%

3.2 Future

Based on estimates for the next years, APEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.79% on average per year.
APEN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 33.84% yearly.
EPS Next Y13.1%
EPS Next 2Y11.79%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year18.29%
Revenue Next 2Y20.22%
Revenue Next 3Y33.84%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APEN. In the last year negative earnings were reported.
Also next year APEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.79%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

APEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

APOLLO ENDOSURGERY INC

NASDAQ:APEN (4/3/2023, 7:15:00 PM)

After market: 9.99 -0.01 (-0.1%)

10

+0.08 (+0.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap475.49M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 55.2%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 1.04
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.35
Quick Ratio 1.89
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-9.99%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y13.1%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)22.01%
Revenue growth 3Y14.87%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y